GLP-1 Statistics: 2026
Usage, pricing, and market data for GLP-1 / weight-loss medications — compiled from primary sources. Free to cite with attribution to WeightSherpa.com.
1 in 9
Americans who used a GLP-1 in 2025
Source: KFF Health Tracking Poll, May 2024
14%
Additional adults who say they want to try one
Source: KFF Health Tracking Poll, May 2024
$149
Lowest monthly cash-pay price tracked in 2026
Source: WeightSherpa price tracker, April 2026
22.5%
Average weight loss at 72 weeks on tirzepatide (Zepbound)
Source: SURMOUNT-1 trial (NEJM, 2022)
15%
Average weight loss on semaglutide 2.4mg (Wegovy)
Source: STEP-1 trial (NEJM, 2021)
20%
Discontinuation rate in year one (all GLP-1s)
Source: JAMA Network Open, 2024
$1B+
2025 US market size for anti-obesity GLP-1s
Source: Morgan Stanley healthcare outlook
Jan 2026
Wegovy pill launch — fastest oral-obesity drug launch ever
Source: FDA approval release
2027
Expected FDA filing for the first once-monthly GLP-1 (MariTide)
Source: Amgen Phase 3 readout
How to cite this page
Use: "WeightSherpa, GLP-1 Statistics 2026 (weightsherpa.com/data/glp1-statistics)". We update these figures quarterly and revise the dates when numbers change.
Press inquiries
Reach us at press@weightsherpa.com.